Core Viewpoint - Longshen Rongfa announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., has received a renewed Drug Production License and a GMP compliance inspection notice from the Gansu Provincial Drug Administration, which is significant for the company's future development [1] Group 1: Regulatory Approvals - Gansu Puan Pharmaceutical has obtained a renewed Drug Production License valid until March 2, 2026 [1] - The production address and scope include various forms of medications such as decoctions, membrane preparations, and raw materials like Naloxone [1] Group 2: Production Capacity and Quality Compliance - The newly constructed production line for liquid preparations, with an annual capacity of 50 million boxes (300 million doses) for cough syrup, has been upgraded to meet GMP standards [1] - The compliance with GMP requirements and readiness for production operations will enhance the market sales and product supply of the cough syrup [1]